Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

Prior to Janus kinase inhibitors, available therapies for myelofibrosis were generally supportive and did not improve survival. This analysis compares efficacy outcomes of patients with myelofibrosis in the control arms (placebo [n=154] and best available therapy [n=73]) from the two phase 3 COntrol...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Mesa, Ruben A., Kiladjian, Jean-Jacques, Verstovsek, Srdan, Al-Ali, Haifa Kathrin, Gotlib, Jason, Gisslinger, Heinz, Levy, Richard, Siulnik, Andres, Gupta, Vikas, Khan, Mahmudul, DiPersio, John F., McQuitty, Mari, Catalano, John V., Hunter, Deborah S., Knoops, Laurent, Deininger, Michael, Cervantes, Francisco, Miller, Carole, Vannucchi, Alessandro M., Silver, Richard T., Barbui, Tiziano, Talpaz, Moshe, Barosi, Giovanni, Winton, Elliott F., Mendeson, Estella, Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth, Lyons, Roger M., Paquette, Ronald, Raza, Azra, Sun, William, Sandor, Victor, Kantarjian, Hagop M., Harrison, Claire
פורמט: Artigo
שפה:Inglês
יצא לאור: Ferrata Storti Foundation 2014
נושאים:
Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3912959/
https://ncbi.nlm.nih.gov/pubmed/23911705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.087650
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים